Long-Term outcomes of cardiac pacing in adults with congenital heart disease  by Walker, Fiona et al.
L
P
F
G
T
A
u
p
l
f
p
a
a
l
f
d
i
a
g
p
a
t
f
p
o
H
o
2
Journal of the American College of Cardiology Vol. 43, No. 10, 2004
© 2004 by the American College of Cardiology Foundation ISSN 0735-1097/04/$30.00
Published by Elsevier Inc. doi:10.1016/j.jacc.2003.12.044ong-Term Outcomes of Cardiac
acing in Adults With Congenital Heart Disease
iona Walker, MD,*† Samuel C. Siu, MD, SM, FACC,*† Shane Woods,* Douglas A. Cameron, MD,*†
ary D. Webb, MD, FACC,*† Louise Harris, MB, CHB, FACC*†
oronto, Ontario, Canada
OBJECTIVES The purpose of this retrospective study was to define long-term outcomes after pacemaker
therapy in adults with congenital heart disease (CHD).
BACKGROUND Adults with CHD represent a unique and expanding population. Many will require
pacemaker or implantable defibrillator therapy, with a lifelong need for re-intervention and
follow-up. They pose technical and management challenges not encountered in other groups
receiving pacing, and the complication and re-intervention rates specific to this population are
not well-defined.
METHODS We reviewed outcomes of 168 adults with CHD, 89 females, mean age 40 years, in whom a
pacemaker or anti-tachycardia device was implanted.
RESULTS Mean age at implant was 28 years with mean pacing duration 11 years at follow-up (range,
0.5 to 38.0). Seventy-two (42%) received initial dual-chamber devices and remained in this
mode, while 23 (14%) went from ventricular to dual-chamber pacing in follow-up. Initial
mode of pacing did not have a significant effect on subsequent atrial arrhythmia. Patients
receiving an initial epicardial system were younger than those paced endocardially (17  12
years vs. 35  16 years, p  0.001) and more likely to undergo re-intervention (p  0.019).
Difficulty with vascular access was encountered in 25 patients (15%), while 45 (27%)
experienced lead-related complications. No significant predictors of lead complications were
identified.
CONCLUSIONS Lead complications were not significantly different for epicardial versus endocardial, nor
physiologic versus ventricular pacing, but a trend toward improved lead survival in patients
receiving endocardial leads at first implant was observed. Adults with CHD remain at risk for
atrial arrhythmias regardless of pacing mode. (J Am Coll Cardiol 2004;43:1894–901)
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2dults with congenital heart disease (CHD) are part of a
nique and expanding patient population. Some of these
atients will require permanent pacemaker (PPM) or defibril-
ator therapy, with the attendant need for re-intervention and
ollow-up over a lifetime. Although the transvenous ap-
roach for implantation is preferred in adults, this may not
lways be technically feasible, not only because of abnormal
natomy but because reparative or palliative surgery may
imit vascular access. Epicardial pacing circumvents the need
or vascular access but often at the expense of long-term lead
urability with an increased requirement for surgical re-
ntervention (1). Adults with CHD therefore pose technical
nd management challenges not encountered in other paced
roups.
Complication and re-intervention rates specific to this
opulation are unknown. Pacing experience in adults with
cquired heart disease is not necessarily representative of
his group, and it may not be appropriate to extrapolate
rom experience in the pediatric paced population. The
urpose of this retrospective study was to define long-term
utcomes after PPM in adults with CHD.
From the *Toronto Congenital Cardiac Centre for Adults, Toronto General
ospital, Toronto, Ontario, Canada; and the †Department of Medicine, University
f Toronto, Toronto, Ontario, Canada.
Manuscript received August 15, 2003; revised manuscript received December 17,m003, accepted December 23, 2003.ETHODS
nclusion criteria. This retrospective study represents our
xperience with PPM, or anti-tachycardia device therapy
ATD), in consecutive adults with CHD (age 18 years as
f July 2000) at the Toronto Congenital Cardiac Centre for
dults (TCCCA). Patients were identified from the pace-
aker implantation registry (Toronto General Hospital)
nd the database of the TCCCA.
xclusion criteria. Patients with pacemakers implanted for
solated congenital complete atrio-ventricular (AV) block or
solated long QT syndrome were excluded. The University
ealth Network Research Ethics Board approved this
tudy.
tudy protocol. The following data were collected from
atient charts: congenital anatomic diagnosis; type and
umber of cardiac surgeries; age at cardiac surgery(s) and at
acemaker implant(s); electrophysiologic (EP) indication
or PPM; type of device and leads implanted/explanted;
ethod of implant (endocardial/epicardial); number, indi-
ation, and age at re-operations/re-interventions; pacing
ode and mode change over time; complications; nature
nd frequency of arrhythmias. Atrial arrhythmias (AT) were
etected by: 1) chart review and electrocardiographic
ECG) documentation of all visits to the TCCCA; and/or
) atrial electrogram and ECG documentation of six
onthly visits to the pacemaker clinic; and, more recently,
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May 19, 2004:1894–901 Pacing in Adults With Congenital Heart Disease) stored logs and electrograms from newer generation
ual-chamber pacemakers. Routine transthoracic echocar-
iograms are performed annually for patients of the TC-
CA. Transesophageal echocardiography and venography
o confirm thrombosis were performed only when clinically
ndicated. We defined lead complications as any of: lead
racture, lead recall, thrombus or vegetation on pacing lead,
r wound infection/erosion. Major clinical complications
nclude venous thrombosis, stroke, or cardiac death.
ollow-up data were updated to December 2001.
tatistical analysis. Statistical analysis was performed us-
ng SPSS for Windows (Version 10.0, SPSS Inc., Chicago,
llinois). Data are presented as a mean  SD. Comparisons
etween patients were performed with the chi-square,
isher exact, or t test as appropriate. The Fisher exact test
as utilized in place of chi-square test when the expected
requency of a cell within a contingency table was 5.
reedom from re-operation, lead complications, and AT
as calculated by the Kaplan-Meier method when the data
ere stratified by the route (endocardial vs. epicardial) and
ode of pacing (dual-chamber or atrial vs. ventricular). Cox
egression was used to identify predictors of lead complica-
ions in follow-up. Univariate predictors of events with a
ignificance 0.10 were entered into a multivariate Cox
roportional hazards model using a backward elimination
lgorithm. Level of statistical significance was set at 0.05
two-sided).
ESULTS
atient demographics. A total of 168 adult patients with
HD were identified from the databases as having a
acemaker or ATD implanted. Of these, 89 were female
nd 79 male, mean age 40 years (range, 17 to 85 years), at
ime of data collection. There was a total of 1,582 paced
ears for the study population, with a mean duration of
acing 11  9 years; median, 10 years; range, 0.5 to 38.0
ears. The first implant for most patients occurred in
dulthood, with 113 first implants in patients 18 years.
ifty-five first implants (33%) were performed in childhood
1 to 18 years), and five of these in infants 1 year of age.
he mean age at first implant for the study population was
8 years. Re-intervention was required in 63% of patients:
9 had a total of two pacemaker interventions, 31 had 3
acemaker surgeries, 16 had 4 pacemaker surgeries, 8 had 5
Abbreviations and Acronyms
AT  atrial arrhythmias
ATD  anti-tachycardia device therapy
AV  atrio-ventricular
CHD  congenital heart disease
EP  electrophysiologic
PPM  permanent pacemaker
TCCCA  Toronto Congenital Cardiac Centre for
Adultsacemaker surgeries, and 12 had 5 pacemaker surgeries. ghe indication for a pacemaker re-intervention was gener-
tor end-of-life characteristics in 57 patients, lead-related in
4, and both indications in 15. A total of 71% of patients
ith an epicardial system and 48% with an endocardial
ystem required 1 pacemaker (p  0.007 by chi-square
est).
The congenital anatomic diagnoses were varied with both
imple and complex defects represented (Table 1). Patients
ith atrial, ventricular, and AV septal defects comprised
lmost 30% of the paced population. Transposition of the
reat arteries and congenitally corrected transposition ac-
ounted for 23%, tetralogy of Fallot 14%, and a substantial
roportion (17%) had complex anatomic CHD (including
ricuspid atresia, pulmonary atresia, single ventricle, and so
n). Details of pacemaker history and outcomes for the four
natomic diagnostic categories with the largest numbers of
atients as per Table 1 are provided in Table 2.
Indications for pacing are outlined in Table 3. Seventy-
ix patients (45%) required pacing peri-operatively after
ardiac surgical repair or palliation. Of the remaining 92
atients, 87 received pacemakers for late sinus node or AV
odal conduction disease, the majority (78 patients) having
ndergone surgery years previously. The indication for
PM was AV block in 65% patients, sinus node disease in
9%, and long QT or tachycardia in the remainder.
To simplify data analysis, anatomic congenital diagnoses
ere grouped into three categories: shunts (including AV
eptal defects with associated AV valve disease)  group 1
n  53), aortic valve disease with or without coarctation of
he aorta  group 2 (n  16), and complex  group 3 (n 
9). The latter included patients with tetralogy of Fallot,
ustard repair, Fontan repair, and double outlet right
entricle. The type of surgical intervention was also subdi-
ided into four categories: none  group 1 (n  10); shunt
losure  group 2 (n  39); valve repair/replacement/
oarctation of the aorta  group 3 (n  21); complex
urgery (Mustard/Fontan, etc.)  group 4 (n  98). The
rrhythmia diagnostic groups were divided into: group 1 
atients with peri-operative sinus or AV nodal disease;
able 1. Congenital Anatomic Diagnosis
Congenital Anatomic
Diagnosis
Number of
Patients (%)
omplex anatomic 29 (17.3%)
TGA 25 (14.9%)
trial septal defects 25 (14.8%)
etralogy of Fallot 24 (14.3%)
entricular septal defects 15 (8.9%)
TGA 14 (8.3%)
ortic valve stenosis 13 (7.7%)
trioventricular septal defect 10 (5.6%)
bstein’s anomaly 7 (4.2%)
oarctation of aorta 3 (1.8%)
ther 3 (1.8%)
omplex anatomic  tricuspid atresia, pulmonary atresia, or single ventricle; DTGA
classic transposition of the great arteries; LTGA  congenitally corrected
ransposition of the great arteries.roup 2  remote or non-surgical disease; and group 3 
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Pacing in Adults With Congenital Heart Disease May 19, 2004:1894–901ong QT/tachycardia as the indication for pacing. The
elationship between the CHD and EP diagnostic groups
Table 4) and type of cardiac surgery and EP diagnostic
roup (Table 5) were both statistically significant. Patients
ndergoing valve surgery, in particular, aortic valve surgery,
ere most likely to require pacing peri-operatively. Patients
ith shunt repair or those requiring complex surgical
ntervention had a greater likelihood of pacemaker require-
ent in follow-up than the former group.
ndocardial versus epicardial pacing. Of 168 patients,
06 (63%) were paced endocardially at first implant, and 62
37%) epicardially. Over time, however, 24 converted from
picardial to endocardial pacing and three from endocardial
o epicardial pacing.
An epicardial pacing system as the initial implant was
ignificantly associated with early surgically induced sinus node
Table 2. Pacemaker History for the Four Anat
Numbers of Patients as per Table 1
Diagnostic Category
EP diagnosis
Surgical AVB
Surgical SSS
Acquired AVB
Acquired SSS
Drug-related
Mode of pacing
AAI/DDD
VVI
Access
Endocardial
Epicardial
Pacemaker implants (number)
1
1
Complications (number of patients)
Lead-related—all
Lead-related—Accufix excluded
AT post-implant
Median freedom from lead complication or re-opera
All patients
Accufix excluded
AAI/DDD  dual-chamber or atrial-based pacing; ASD 
DTGA  classic transposition of the great arteries; EP  e
Fallot; VVI  ventricular pacing.
able 3. Indications for Pacing
Indication for
Pacing
Number of
Patients (%) Etiology
urgical AVB 62 (36.9%) Peri-operative
urgical SSS 14 (8.3%) 45%
cquired AVB 44 (26.1%) Remote or no surgery
ongenital AVB 1 (0.5%) 52%
cquired SSS 32 (19%)
rug-induced 5 (2.9%)
P-induced AVB 3 (1.8%)
inus bradycardia 2 (1.2%) Other
achycardia 4 (2.4%) 3%
ong QT 1 (0.5%)pVB  heart block; EP  electrophysiologic; SSS  sinus node disease.isease or AV block (60% vs. 40% patients, p  0.015 by
hi-square test). Patients in whom the initial implant was
picardial were also younger (17 12 years vs. 35 16 years,
 0.001) and more likely to undergo repeat pacemaker
urgical interventions in follow-up (74% vs. 57% patients with
1 pacemaker intervention, p  0.023 by chi-square test).
he time from implant to re-operation for patients receiving
n initial epicardial versus endocardial implant (Accufix
Telectronics Pacing Systems, Colorado] leads excluded) was,
owever, not significantly different (median survival 7 vs. 8
ears, respectively, p  0.31). Lead complications—lead re-
alls, fractures, and so on—occurred in 36% and 26% of
atients with epicardial and endocardial systems, respectively,
ut were not significantly different between the two groups (p
0.64 by chi-square test). When patients with transvenous
ccufix leads were excluded, there was a trend toward im-
roved lead survival in patients receiving endocardial leads as
able 4. Relationship Between Congenital Anatomic Diagnosis
nd Indication for Pacing
Congenital
Heart Disease
iagnostic Group
Electrophysiologic Diagnostic Group and
Indication for Pacing
Peri-Operative
Remote or
No Surgery Other
hunts (n  53) 25 (47%) 26 (49%) 2 (4%)
alvular/coarctation
(n  16)
13 (81%) 3 (19%) —
omplex (n  98) 38 (38%) 58 (59%) 3 (3%)
Diagnostic Categories With the Largest
Complex
n  29
DTGA
n  25
ASD
n  25
TOF
n  25
11 5 7 8
5 — 6 1
8 7 2 8
4 12 10 5
1 1 — 2
18 15 11 9
11 10 14 15
9 18 21 15
20 7 4 9
21 18 18 14
8 7 7 10
7 8 7 5
5 4 1 3
10 17 15 9
years)
6 4 6 5
6 5 6 6
septal defect; AT  atrial tachycardia; AVB  heart block;
hysiologic; SSS  sinus node disease; TOF  tetralogy ofomic
tion (
atrial
lectrop 0.026 by Fisher exact test.
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May 19, 2004:1894–901 Pacing in Adults With Congenital Heart Diseaseheir first implant (mean survival, 24.2 vs. 23.8 years, p 
.078) (Fig. 1).
ode of pacing. The mode of pacing and change in mode
ver time is summarized in Table 6. Seventy-two (42%)
atients received dual-chamber implants at the outset and
emained in this mode, while 23 (14%) were upgraded from
entricular to dual-chamber pacing in follow-up. Atrial
acing was observed in 10%, with only one patient upgraded
o dual-chamber and one converted to ventricular pacing in
ollow-up. Pulse generator longevity (median time to re-
lacement) was not significantly associated with either
nderlying congenital anatomic diagnosis (7 vs. 8 years,
on-complex vs. complex, p  0.18) or mode of pacing (7
s. 8 years, ventricular vs. dual-chamber pacing, p  0.27).
imilarly, freedom from lead complications (Accufix leads
xcluded) was not significantly different for patients with
able 5. Relationship Between Surgical Intervention and
ndication for Pacing
Cardiac Surgery Group
Electrophysiologic Diagnostic Group and
Indication for Pacing
Peri-Operative
Remote or
No Surgery Other
one (n  10) — 9 (90%) 1 (10%)
hunt closure (n  39) 18 (46%) 20 (51%) 1 (3%)
alve or coarctation
repair (n  21)
15 (71%) 6 (29%) —
omplex (n  98) 43 (44%) 52 (53%) 3 (3%)
 0.0038 by Fisher exact test.
igure 1. Kaplan-Meier survival of freedom from lead complication for end
xcluded). N  number of patients at the various follow-up intervals.hysiologic (dual-chamber or atrial-based pacing) compared
ith ventricular pacing (p  0.29) (Fig. 2).
ncidence of AT. Sustained AT were observed in 76
atients (45%). Five variables were evaluated as possible
redictors for AT after pacing: history of AT before pacing,
hysiologic pacing (dual-chamber and atrial-based pacing),
ge at initial implant  the median age of 23 years, gender,
nd complex anatomy. Univariate analysis identified AT
efore pacing as significant (p  0.001) and complex
natomy as of borderline significance (p  0.10). Subse-
uent multivariate analysis, however, confirmed AT before
mplant was the only independent predictor of arrhythmia
fter implant (p  0.001, risk ratio  7.41). Physiologic
acing did not appear to be protective against subsequent
T when compared with ventricular pacing (Fig. 3).
omplications. Forty-five patients (27%) experienced
ead-related complications, with some patients experiencing
ore than one lead-related event. Lead fractures were
ncountered in 17 patients (2 of whom also had leads on
ecall), while primary lead recalls accounted for lead replace-
ent in 28. There were 22 lead complications in 1,582
atient years of follow-up or 1.4 events per 100 patient years
f follow-up. As a consequence of anatomic and surgical
onstraints, transvenous active fixation atrial and/or ventric-
lar leads were implanted in many of these patients, and
oncerns with the Accufix lead system accounted for the
ajority (27 patients) of these recalls. Three patients (2
ost-Mustard repair, 1 atrio-pulmonary Fontan repair) were
al (solid line) versus epicardial (broken line) pacing systems (Accufix leadsocardi
i
t
e
t
p
W
f
t
a
t
a
t
p
c
p
a
c
a
u
fi
a
t
l
n
(
p
D
o
F
w
p
h
s
I
p
D
A
p
c
t
r
p
t
T
A
F
l
1898 Walker et al. JACC Vol. 43, No. 10, 2004
Pacing in Adults With Congenital Heart Disease May 19, 2004:1894–901dentified by transthoracic echocardiography as having
hrombus on their pacing leads. Two of these patients were
xperiencing sustained AT at the time of detection, and the
hird had paroxysmal atrial flutter. Vegetations on the
acing leads occurred in one patient in long-term follow-up.
ound infections occurred in six (in association with lead
racture in 2, lead recall in 3) and pulse generator erosion in
wo (in association with lead recall in one, lead malposition
nd thrombus in the other).
A 67-year-old patient with established atrial flutter and a
ransvenous ventricular pacemaker suffered a stroke while
waiting device closure of an atrial septal defect. Although
he stroke may have been attributable to the arrhythmia, a
aradoxical embolus originating from the pacemaker lead
ould not be excluded.
Difficulty with vascular access was encountered in 25
atients (15%): 11 had venous obstruction, nine had anom-
lous veins, and venous access was precluded in five as a
able 6. Initial and Subsequent Mode of Pacing in Follow-Up
First Implant Most Recent Implant Number of Patients (%)
AAI AAI 16 (10%)
AAI VVI 1 (1%)
AAI DDD 1 (1%)
VVI VVI 51 (30%)
VVI DDD 23 (14%)
VVI AAI 1 (1%)
DDD DDD 72 (42%)
DDD VVI 3 (2%)
AI atrial-based pacing; DDD dual-chamber pacing; VVI ventricular pacing.
igure 2. Kaplan-Meier survival of freedom from lead complication for ph
eads excluded). N  number of patients at the various follow-up intervals.onsequence of previous surgery. One patient experienced
cute subclavian vein thrombosis. Five variables were eval-
ated as possible predictors for lead complication: age at
rst implant, number of cardiac surgeries, complexity of
natomic diagnosis, gender, and mode of pacing. None of
hese were independently predictive. The incidence of
ead complications when Accufix leads were excluded was
ot significantly different for patients with physiologic
dual-chamber or atrial-based) compared with ventricular
acing.
eaths. Of four deaths in follow-up, two were sudden and
ccurred in patients with previously repaired tetralogy of
allot and Mustard repair, respectively. No further details
ere available regarding these deaths. One patient with
revious atrial septal defect repair and associated pulmonary
ypertension died of congestive heart failure. The circum-
tances of the remaining death are unknown.
mplantable defibrillator/ATD. Four patients had im-
lantable defibrillators, and three had atrial ATD.
ISCUSSION
s a consequence of the ability to surgically repair or palliate
atients with complex CHD, 85% of those born with
ongenital defects will survive to adulthood (2). Many of
hese patients will have a life-long need for pacing as a direct
esult of such surgery, but others may come to require
acing later in life. Yet others may require device implan-
ation to provide anti-tachycardia pacing or to facilitate drug
gic (solid line) versus ventricular (broken line) mode of pacing (Accufixysiolo
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May 19, 2004:1894–901 Pacing in Adults With Congenital Heart Diseaseherapy of tachyarrhythmias. Improved lead design and
apidly evolving device technology have provided the clini-
ian with more options in patient management and ever-
xpanding indications for device implantation (3,4). Adults
ith CHD, however, pose management and technical
hallenges not encountered in other paced groups.
Our cohort of 168 consecutive adult patients with CHD
nd device therapy had a median follow-up of 10 years. The
atient with the longest duration of pacing, still actively
ollowed, received her first pacemaker in 1963. The long
uration of follow-up enabled us to determine the implica-
ions and outcomes of long-term pacing in this unique
atient population. Two-thirds of patients required two or
ore pacemaker interventions in follow-up. Dual-chamber
r atrial-based pacing was accomplished and maintained in
he majority of patients (66%), with only four converting to
entricular pacing in follow-up. The incidence of lead
omplications was 3% per patient-years, and wound infec-
ions or pulse generator erosion was observed in 5% of
atients overall.
Lead-related complications (lead fracture and recall) and
ifficulty with vascular access were commonly encountered,
ccurring in 27% and 15% of patients, respectively, with
ome patients experiencing more than one lead-related
vent. The incidence of lead complications (Accufix leads
xcluded) was not significantly different for patients with
hysiologic (dual-chamber or atrial-based) pacing compared
ith ventricular pacing. In a previous study from a pediatric
igure 3. Kaplan-Meier survival of freedom from atrial arrhythmias for phy
atients with congenital heart disease. N  number of patients at the varopulation with CHD (5), atrial, as opposed to ventricular, fead placement was identified as predictive of subsequent
ead failure. Dual-chamber or “physiologic” pacing in the
dult population without CHD has traditionally been
iewed as the preferred mode of pacing, as there is sugges-
ive evidence this may be associated with a lower risk of
troke, atrial fibrillation, and death (6–8). A recent multi-
enter study comparing ventricular versus physiologic pac-
ng, however, failed to demonstrate a significant difference
n end points of heart failure, stroke, or death although
hysiologic pacing was associated with a small, late reduc-
ion in the risk of atrial fibrillation (9). Atrial arrhythmias,
requently encountered in the adult with CHD, contribute
ubstantially to morbidity and mortality in this population
10). Any management strategy reducing the incidence of
uch arrhythmias would be a welcome contribution. In this
ohort of adults with CHD, a substantial proportion of
atients (45%) experienced sustained AT after pacing.
ultivariant analysis identified only AT before pacing as
redictive of arrhythmia subsequent to pacing. Although
here was a progressive occurrence of AT for this group of
atients in ongoing follow-up, we were unable to demon-
trate a significant effect of the mode of pacing on the
ncidence of subsequent AT (Fig. 3). In a small cohort of
ontan patients, Fishberger et al. (11) found AV synchrony
ith dual-chamber pacing conferred long-term survival
enefit compared with ventricular pacing, but this did not
each statistical significance.
The transvenous route was utilized as the initial approach
ic (solid line) versus ventricular (broken line) mode of pacing in 168 adult
ollow-up intervals.siologor pacing in the majority of our patients (68%) and, of
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Pacing in Adults With Congenital Heart Disease May 19, 2004:1894–901hose implanted epicardially, a further 39% were subse-
uently converted to a transvenous system. Lead complica-
ions, although more frequent in those with epicardial
ystems, did not differ significantly between those with
picardial versus endocardial pacing. This was, in part,
ccounted for by the frequent use of active fixation atrial
nd/or ventricular leads, specifically the Accufix lead, in our
atients with transvenous systems. The Accufix leads were
ubject to recall in the mid-1990s, secondary to a design
aw reported to be associated with fatalities (12). Active
xation leads are often required in this population either as
consequence of the underlying anatomic substrate or of the
revious cardiac surgery—for example, to accomplish trans-
enous pacing in the non-trabeculated morphologic left
entricle after Mustard repair. When patients with Accufix
eads were excluded, there was a trend toward improved lead
urvival in patients receiving endocardial leads as their first
mplant.
Patients with epicardial pacing systems were younger at
nitial implant and more likely to undergo repeat pacemaker
urgery in follow-up. These findings are consistent with a
ecent report comparing these two approaches in a pediatric
opulation (1). With a follow-up of 3 to 3.4 years in a
opulation with a mean age of 5.3 years, Sachweh et al. (1)
ound lead-related re-operations more frequently in patients
ith epicardial leads as a consequence of higher initial and
ong-term pacing stimulation thresholds. The latter may no
onger be applicable, however, to the current generation of
picardial systems, where improved lead design and tech-
ology have resulted in improved long-term stimulation
hresholds. Two recent publications (13,14) attest to the
ong-term durability of steroid-eluting epicardial leads in
ediatric patients with CHD.
Difficulty with vascular access was encountered in 15% of
atients as a consequence of anomalous veins, previous
urgery, or venous obstruction. The latter has been reported
o occur in 30% to 45% of patients after transvenous pacing
nd is usually asymptomatic (15). Only one patient experi-
nced acute venous thrombosis. The majority of our patients
ave had more than one transvenous pacing system im-
lanted with as many as three to four leads traversing a
ingle vein over the duration of follow-up. With the recent
dvent of laser extraction systems for lead removal (16),
ultiple leads in single veins should no longer be encoun-
ered, and new leads can be introduced even in the presence
f venous obstruction. For patients with a history of
revious cardiac surgery, it is helpful to document venous
natomy before pacemaker implant with venography. In
hose with more complex repairs, an operator familiar with
he congenital anatomy should undertake the implant. In
ddition to issues of venous access, cardiac access via the
ransvenous route may also be precluded—for example, the
atient with an atrio-pulmonary Fontan repair requiring
entricular pacing. Consideration should be given to intra-
perative lead placement at cardiac surgical repair for
onditions known to be associated with bradyarrhythmias wnd where transvenous access will be precluded after surgery
e.g., post-Fontan repair). Subsequent extensive adhesions
ay limit satisfactory epicardial atrial lead placement in
articular.
Thrombus on pacing leads was observed in three patients,
ll of whom had a history of AT, and one additional patient
uffered a stroke possibly attributed to the pacemaker.
lthough echocardiography would have been performed
outinely in follow-up, it is certainly feasible that the
ncidence of thrombus has been underestimated. Thrombus
n transvenous pacing leads in adults with acquired heart
isease is an established complication of pacing (17). It is
ikely that CHD patients in whom enlarged atria and
ow-velocity flow states are frequently encountered (18) are
t increased risk for such thrombus. In the Fishberger et al.
eries (11), no embolic complications were observed in 12
ontan patients receiving transvenous atrial pacing, only
wo of whom were anti-coagulated with coumadin. Throm-
us formation and embolic complications are not described
n the Gillette et al. (19) report of pacing outcomes after
ustard repair, nor in other studies of long-term trans-
enous pacing in patients with CHD (20,21).
tudy limitations. A large series of long-term pacing
utcomes in this population has not been previously re-
orted; thus, this was a preliminary study and is, therefore,
ypothesis-generating. This was a retrospective study with
ata collection limited to variables available from clinical
ecords. Certain complications that are more likely to be
symptomatic, such as lead thrombus, may be underesti-
ated. The number of patients with implantable defibril-
ators and ATD was insufficient for separate analysis of the
utcomes of these devices. A total of 16% of patients did not
ave follow-up data in the last two years of data collection.
t was not possible to determine lesion-specific outcomes
such as comparing outcomes between different types of
hunts) due to the small number of patients within each
natomic subgroup.
onclusions. Historically, pacing in the patient with
HD was primarily required for AV block, after repair of
eptal defects and tetralogy of Fallot. In the current era, the
ncidence of surgical AV block in these lesions has decreased
ut has been offset by a corresponding increase in pacing
fter repair of increasingly complex defects. Furthermore,
ndications for pacing have evolved beyond bradycardia
upport to include hemodynamic optimization and therapy
or tachyarrhythmias. This has important implications for
he adult with CHD, in whom ventricular dysfunction and
rrhythmias are frequently encountered. Planning for device
herapy in these patients necessitates consideration of ana-
omic and surgical data with careful attention to coexisting
rrhythmias, issues of vascular access, and intracardiac
hunting. In this study, the incidence of lead complications
Accufix leads excluded) was not significantly different for
picardial versus endocardial pacing, nor for physiologic
ersus ventricular pacing. Disappointingly, the adult patient
ith CHD remains at risk for AT in follow-up regardless of
t
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echniques, the trend toward earlier age for surgical correc-
ion, and newer AT preventative algorithms may yet alter
his outcome.
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